Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2012 - 2026)

Fate Therapeutics has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $284.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 28.53% year-over-year to $284.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 29.2% YoY), and the FY2025 full-year result was $318.9 million, down 27.63% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $284.9 million, down from $318.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $858.4 million in Q1 2022, with the low at $284.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $537.5 million across 5 years, with a median of $528.8 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 8.98% — and 2025, when it tumbled 30.57%.
• Fate Therapeutics' Liabilities and Shareholders Equity stood at $705.6 million in 2022, then declined by 28.25% to $506.2 million in 2023, then declined by 12.94% to $440.7 million in 2024, then decreased by 27.63% to $318.9 million in 2025, then declined by 10.67% to $284.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $284.9 million (Q1 2026), $318.9 million (Q4 2025), and $343.7 million (Q3 2025), per Business Quant data.